Companies such as Amgen (AMG 133 is in mid stage trials), Innovent Biologics and Lilly (Mazdutide, in phase 2 trials) are working on dual agonists for obesity
It may thus lay a basis for further studies using electronic health records or patient-reported data with the purpose of understanding who the potential off-label patients are and to what degree they benefit from treatment
In a frequently cited in-vitro study, BPC-157 promoted the outgrowth of tendon fibroblasts from explants, enhanced their migration, and improved cell survival under stress, effects linked to activation of the FAK-paxillin pathway
Of course, as a functional medicine practitioner, I make sure to assess and address any underlying gut and hormone imbalances first, but I also look to the current research to take my recommendations to the next level
This guidance clarifies the need for developers to explicitly define context of use and demonstrate that a NAM is biologically relevant, technically robust, and fitforpurpose to support regulatory decisionmaking within that context
What you choose to do with that is up to you
_edited.png)
